Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Could This Be the Right Deal for AstraZeneca?

Amarin has been an exciting stock to follow since the company gained approval from the Food and Drug Administration for its triglyceride-lowering drug Vascepa this summer. The FDA's delay in deciding whether Vascepa qualifies for NCE status has weighed heavily on the stock, but buyout speculation has buoyed Amarin's share price lately.

Recently, British newspaper The Daily Mail suggested that pharma giant AstraZeneca  (NYSE: AZN  ) might be interested in adding Vascepa to its product portfolio. While an Amarin buyout could just be speculation -- and neither company has publicly initiated negotiations -- could this deal hypothetically make sense? Would this be the right acquisition for AstraZeneca? Given that Vascepa's NCE status is still not final, would the timing be right?

In the following video, health care analysts Max Macaluso and Brenton Flynn take an in-depth look at these issues.

The biotech space can make or break investors over-night, and, while Amarin's future is still unclear, the company could have huge potential. If you're an investor looking for more insight on Amarin, don't invest a dollar before reading everything you need to know about Amarin. This new premium research report can help you weigh the opportunities and risks associated with this stock. Click here now to keep reading.

Max Macaluso, Ph.D. and Brenton Flynn have no positions in the stocks mentioned above. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2073824, ~/Articles/ArticleHandler.aspx, 10/26/2016 3:48:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,217.24 47.97 0.26%
S&P 500 2,139.91 -3.25 -0.15%
NASD 5,253.48 -29.92 -0.57%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 12:01 PM
AZN $4785.44 Down -26.06 -0.54%
AstraZeneca CAPS Rating: No stars
AZN $29.62 Down -0.18 -0.59%
AstraZeneca CAPS Rating: ****